NASDAQ:NBIX

Neurocrine Biosciences - NBIX Earnings Date, Estimates & Call Transcripts

$105.63

+0.75 (+0.72%)

(As of 08/12/2022 12:00 AM ET)

Add

Compare

Today's Range: $105.19
▼
$106.96
50-Day Range: $88.93
▼
$107.66
52-Week Range: $71.88
▼
$109.26

Volume: 1.23 million shs
Average Volume: 746,506 shs
Market Capitalization: $10.10 billion

P/E Ratio: 960.36
Dividend Yield: N/A
Price Target: $113.60

Earnings Per Share Revenue

NBIX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

NBIX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Neurocrine Biosciences Analyst Forecasts

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate	Company Guidance
Q1 2022	5	$0.19	$0.50	$0.35
Q2 2022	5	$0.47	$0.79	$0.61
Q3 2022	5	$0.59	$0.75	$0.65
Q4 2022	5	$0.59	$0.88	$0.73
FY 2022	20	$1.84	$2.92	$2.35
Q1 2023	2	$0.51	$0.72	$0.62
Q2 2023	2	$0.74	$1.00	$0.87
Q3 2023	3	$0.93	$1.16	$1.05
Q4 2023	3	$1.12	$1.31	$1.24
FY 2023	10	$3.30	$4.19		$3.78

NBIX Earnings Date and Information

Neurocrine Biosciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 7th, 2022 based off prior year's report dates.

Neurocrine Biosciences Earnings History by Quarter

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
11/7/2022 (Estimated)
5/4/2022	Q1 2022	$0.33	$0.14	($0.19)	$0.14	$304.07 million	$310.60 million
2/11/2022	Q4 2021	$0.61	($0.08)	($0.69)	($0.08)	$317.72 million	$312.00 million
11/1/2021	9/30/2021	$0.51	$0.23	($0.28)	$0.23	$297.02 million	$296.00 million
8/2/2021	6/30/2021	$0.52	$0.43	($0.09)	$0.43	$274.47 million	$288.90 million
5/4/2021	3/31/2021	$0.47	$0.33	($0.14)	$0.33	$247.81 million	$236.60 million
2/3/2021	12/31/2020	$0.59	$3.58	+$2.99	$3.58	$260.43 million	$247.90 million
11/14/2020	9/30/2020	$0.11	($0.62)	($0.73)	($0.62)	$282.59 million	$258.80 million
8/3/2020	6/30/2020	$0.65	$0.81	+$0.16	$0.81	$261.66 million	$302.40 million
5/6/2020	3/31/2020	$0.56	$0.82	+$0.26	$1.25	$226.29 million	$237.10 million
2/4/2020	Q4 19	$0.75	$0.35	($0.40)	$0.35	$231.54 million	$244.10 million

11/4/2019	Q3 2019	$0.63	$0.56	($0.07)	$1.02	$211.31 million	$222.09 million
7/29/2019	Q2	$0.24	$0.37	+$0.13	$0.20	$161.79 million	$183.58 million
4/29/2019	3/31/2019	($1.05)	($1.12)	($0.07)	($1.12)	$136.77 million	$138.40 million
2/5/2019	12/31/2018	$0.14	$0.19	+$0.05	$0.19	$132.32 million	$131.49 million
11/5/2018	9/30/2018	$0.48	$0.52	+$0.04	$0.52	$151.51 million	$151.80 million
7/31/2018	Q2 2018	($0.18)	($0.07)	+$0.11	($0.07)	$84.11 million	$96.90 million
4/30/2018	Q1 2018	($0.29)	($0.47)	($0.18)	($0.47)	$65.17 million	$71.08 million
2/13/2018	Q4 2017	$0.18	$0.07	($0.11)	$0.07	$94.00 million	$94.52 million
11/1/2017	Q3 2017	($0.49)	($0.13)	+$0.36	($0.13)	$29.38 million	$60.77 million
8/3/2017	Q2 17	($0.67)	($0.68)	($0.01)	($0.68)	$0.61 million	$6.34 million
5/9/2017	Q1 17	($0.67)	($0.90)	($0.23)	($0.90)	$3.00 million
2/14/2017	Q416	($0.55)	($0.51)	+$0.04	($0.51)	$4.55 million
11/2/2016	Q316	($0.57)	($0.43)	+$0.14	($0.43)
8/3/2016	Q2 2016	($0.50)	($0.46)	+$0.04	($0.46)
5/5/2016	Q1	($0.29)	($0.22)	+$0.07	($0.22)	$15.43 million	$15.00 million
2/11/2016	Q415	($0.32)	($0.34)	($0.02)	($0.34)	$3.33 million
10/29/2015	Q315	($0.25)	($0.40)	($0.15)	($0.40)	$6.66 million
7/29/2015	Q2	($0.2860)	($0.28)	+$0.0060	($0.28)	$0.41 million
4/30/2015	Q115	($0.30)	($0.01)	+$0.29	($0.01)		$19.76 million
2/9/2015	Q414	($0.24)	($0.26)	($0.02)	($0.26)
11/3/2014	Q314	($0.21)	($0.21)		($0.21)
8/6/2014	Q214	($0.18)	($0.18)		($0.18)	$0.12 million
4/30/2014	Q114	($0.19)	($0.17)	+$0.02	($0.17)	$0.78 million
2/6/2014	Q4 2013	($0.17)	($0.16)	+$0.01	($0.16)	$0.79 million	$0.73 million
10/29/2013	Q3 2013	($0.20)	($0.17)	+$0.03	($0.17)	$0.79 million	$0.73 million
7/25/2013	Q2 2013	($0.20)	($0.18)	+$0.02	($0.18)	$0.77 million	$0.73 million
5/2/2013	Q1 2013	($0.18)	($0.18)		($0.18)	$1.07 million	$0.70 million
2/8/2013	Q4 2012	($0.08)	$0.14	+$0.22		$9.43 million	$21.90 million
10/31/2012	Q312	($0.05)	($0.05)			$10.28 million	$9.40 million
7/31/2012		($0.03)	($0.01)	+$0.02
5/2/2012			($0.01)	($0.01)
2/8/2012	Q4 2011	$0.01	$0.02	+$0.01	$0.02
10/31/2011		$0.19	$0.56	+$0.37
7/28/2011		$0.04	$0.04
5/3/2011		$0.05	$0.05
2/10/2011		$0.04	$0.05	+$0.01
10/28/2010	Q3 2010	$0.05	$0.06	+$0.01	$0.06
7/28/2010	Q2 2010	($0.17)	($0.09)	+$0.08	($0.09)
4/28/2010	Q1 2010	($0.24)	($0.20)	+$0.04	($0.21)
2/3/2010	Q4 2009	($0.28)	($0.22)	+$0.06	($0.24)
10/28/2009	Q3 2009	($0.35)	($0.21)	+$0.14	($0.21)
7/29/2009	Q2 2009	($0.41)	($0.37)	+$0.04	($0.35)
5/5/2009	Q1 2009	($0.38)	($0.38)		($0.25)
2/3/2009	Q4 2008	($0.47)	($0.75)	($0.28)	($0.75)
10/28/2008	Q3 2008	($0.52)	($0.46)	+$0.06	($0.46)
7/30/2008	Q2 2008	($0.52)	($0.55)	($0.03)	($0.55)
4/30/2008	Q1 2008	($0.54)	($0.55)	($0.01)	($0.55)
2/5/2008	Q4 2007	($0.84)	($0.71)	+$0.13	$1.93

Neurocrine Biosciences Earnings - Frequently Asked Questions

When is Neurocrine Biosciences's earnings date?: Neurocrine Biosciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 7th, 2022 based off last year's report dates. Learn more on NBIX's earnings history.

How much revenue does Neurocrine Biosciences generate each year?: Neurocrine Biosciences (NASDAQ:NBIX) has a recorded annual revenue of $1.13 billion.
How much profit does Neurocrine Biosciences generate each year?: Neurocrine Biosciences (NASDAQ:NBIX) has a recorded net income of $89.60 million. NBIX has generated $0.11 earnings per share over the last four quarters.
What is Neurocrine Biosciences's price-to-earnings ratio?: Neurocrine Biosciences (NASDAQ:NBIX) has a trailing price-to-earnings ratio of 960.36 and a forward price-to-earnings ratio of 60.02.
What is Neurocrine Biosciences's EPS forecast for next year?: Neurocrine Biosciences's earnings are expected to grow from $1.76 per share to $3.88 per share in the next year, which is a 120.45% increase.

More Earnings Resources from MarketBeat

Earnings Tools:

Earnings By Country:

Latest Articles:

Upcoming Earnings:

BHP Group (8/16/2022)
Walmart (8/16/2022)
Home Depot (8/16/2022)
Cisco Systems (8/17/2022)
Analog Devices (8/17/2022)
Synopsys (8/17/2022)
TJX Companies (8/17/2022)
Target (8/17/2022)
Lowe's Companies (8/17/2022)
NetEase (8/18/2022)

This page (NASDAQ:NBIX) was last updated on 8/13/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources